ClinicalTrials.gg
RecruitingNCT06747117STRIDE IIUpdated Aug 31, 2026

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

An observational study in Lower Extremity Acute Limb Ischemia and LE ALI, sponsored by Penumbra Inc.. Recruiting at 45 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Penumbra Inc. · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Ischemia with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Ischemia · United States.

Planned enrollment
16th of 53
300 · median 191
Started
2025
with 4 others
Observational
53 of 155
11 open now
Primary completion
2028-06
later than 17 of 23 live
Registered
150th of 155
by date
Lead sponsor
3 of 155
Penumbra Inc.

Among the 155 studies in Ischemia with a site in United States, this one is the 16th largest by planned enrollment of the 53 observational ones that give a count, is one of 5 that started in 2025, is one of 53 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 150th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

20 of the 155 studies in Ischemia with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Ischemia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI).

03

Conditions studied

  • Lower Extremity Acute Limb Ischemia
  • LE ALI

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients that present with LE ALI who are eligible for mechanical thrombectomy using the Indigo Aspiration System

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Patients with a confirmed diagnosis of lower limb arterial occlusion located in the common iliac or below, with a minimum of 2 cm of proximal patency in the common iliac
  • Acute occlusion with symptom duration of 14 days or less at presentation
  • ALI Rutherford Category I, IIa or IIb
  • treatment with the Indigo Aspiration System using Computer Assisted Vacuum Thrombectomy (CAVT) aspiration tubing
  • is obtained from either patient or legally authorized representative (LAR) per Institutional Review Board/Ethics Committee requirements
  • Previously enrolled patients presenting with a new acute occlusion in the contralateral limb meeting all eligibility criteria may be re-enrolled if the new acute occlusion is greater than 30 days from the initial index procedure

Exclusion criteria

Exclusion Criteria:

  • \<1 year
  • Target vessel size \<2 mm
  • Target thrombus is in the aorta or isolated profunda artery
  • Prior major amputation (proximal to the tarsometatarsal joint) in the target limb
  • Prior minor amputation in the target limb within the past 6 months that is not completely healed or cannot bear weight
  • LE ALI secondary to dissection, vasculitis, or target vessel trauma, including iatrogenic etiology from treatment of a proximal location in the target limb, and non-thrombotic material such as tumor fragments, fat emboli, septic emboli, and foreign bodies
  • Target thrombus in a vein bypass graft, previously revised bypass grafts, bypass grafts placed \< 3 months prior to index ALI symptom onset, or bypass grafts with a distal anastomosis below the popliteal artery
  • Treatment of the index event with thrombolytics or any other endovascular or open surgical method prior to enrollment
  • Pregnancy
  • or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated
  • Other medical, behavioral, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  • Current participation in another drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with lower extremity acute limb ischemia

    Device: Indigo Aspiration System

    Device: Indigo Aspiration System

Interventions

  • DeviceIndigo Aspiration System

    Mechanical aspiration thrombectomy with the Indigo Aspiration System.

06

What researchers measure

Primary outcomes

  1. Target Limb Salvage Rate

    Time frame: 30 Days Post-Procedure

Secondary outcomes

  1. Technical Success

    Technical success by treated segment defined as Thromboaspiration in Peripheral Ischemia (TIPI) 2/3 flow immediately post procedure by physician visual assessment of intraprocedural angiography

    Time frame: Immediate Post Procedure

  2. Primary Patency at 30 Days

    Time frame: 30 Days Post-Procedure

  3. Rates of Device-related Major Bleeding

    Time frame: Procedure, 30 Days, and 180 Days Post-Procedure

  4. Rates of Device-related Distal Embolization

    Time frame: During Procedure

  5. Rates of Device-related Serious Adverse Events (SAE)

    Time frame: Procedure, 30 Days, and 180 Days Post-Procedure

  6. Mortality

    All cause mortality at 30 and 180 days

    Time frame: 30 Days and 180 Days Post-Procedure

07

Study locations

44 of 45 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 70 observational studies under Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartActual
May 18, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jan 2029
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747117
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
May 18, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Aug 31, 2026

Study contacts

Marina Mello
Contact
mmello@penumbrainc.com
+14078108634
Jemymah Allen
Contact
jallen@penumbrainc.com
+13109485738
Daniel Clair, MD
principal investigator · Vanderbilt University Medical Center
Dierk Scheinert, MD
principal investigator · Universitätsklinik Leipzig

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion